Department of Encephalopathy, Chongqing Hospital of Traditional Chinese Medicine, Chongqing, China.
Department of Encephalopathy, Chongqing Hospital of Traditional Chinese Medicine, Chongqing, China.
Am J Emerg Med. 2021 Dec;50:784-788. doi: 10.1016/j.ajem.2021.07.062. Epub 2021 Aug 11.
It is not well established to use vitamin D supplementation for migraine, and this meta-analysis aims to explore the efficacy of vitamin D for migraine patients.
PubMed, EMbase, Web of science, EBSCO and Cochrane library databases were systematically searched up to May 2021, and we included randomized controlled trials (RCTs) exploring the effect of vitamin D for migraine patients.
Six RCTs and 301 patients were included in the meta-analysis. Compared with control group in migraine patients, vitamin D supplementation could remarkably decrease headache attacks per month (MD = -2.74; 95% CI = -3.82 to -1.67; P < 0.00001), headache days per month (MD = -1.56; 95% CI = -2.44 to -0.68; P = 0.0005) and MIDAS score (MD = -5.72; 95% CI = -10.90 to -0.54; P = 0.03), but demonstrated no obvious influence on attack duration (MD = -2.20; 95% CI = -7.38 to 2.97; P = 0.40) or headache severity (MD = -0.56; 95% CI = -1.18 to 0.06; P = 0.08).
Vitamin D supplementation provided additional benefits to treat migraine.
目前对于使用维生素 D 补充剂治疗偏头痛还没有明确的结论,本荟萃分析旨在探讨维生素 D 治疗偏头痛患者的疗效。
系统检索了 PubMed、EMbase、Web of science、EBSCO 和 Cochrane 图书馆数据库,截至 2021 年 5 月,纳入了探索维生素 D 对偏头痛患者影响的随机对照试验(RCT)。
共有 6 项 RCT 和 301 名患者纳入荟萃分析。与对照组相比,维生素 D 补充剂可显著减少偏头痛患者每月的头痛发作次数(MD = -2.74;95%CI = -3.82 至 -1.67;P < 0.00001)、每月头痛天数(MD = -1.56;95%CI = -2.44 至 -0.68;P = 0.0005)和 MIDAS 评分(MD = -5.72;95%CI = -10.90 至 -0.54;P = 0.03),但对头痛持续时间(MD = -2.20;95%CI = -7.38 至 2.97;P = 0.40)或头痛严重程度(MD = -0.56;95%CI = -1.18 至 0.06;P = 0.08)无明显影响。
维生素 D 补充剂对治疗偏头痛有额外的益处。